Diligence memo · auto-generated · as of July 3, 2026

Clear Clinic & Schweiger Dermatology Management Company, LLC

Clear Clinic & Schweiger Dermatology Management Company, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Clear Clinic & Schweiger Dermatology Management Company, LLC operates in Other Health Care, based in NEW YORK.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Clear Clinic & Schweiger Dermatology Management Company, LLC has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $12M on 2014-11-28.

Most recent recorded round closed around 2014-11-28.

Valuation (modeled)modeled

Provath models Clear Clinic & Schweiger Dermatology Management Company, LLC at approximately $238M (range $15M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.97× the median modeled value of Series A Other Health Care companies in 2013–2015 (187 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 20 months.

Last raise 11.6 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 5.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 80% of Other Health Care peers (5377 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Imagine Health, Inc., Spruce Health, Inc., Inova Labs, Inc., Cephea Valve Technologies, Inc., ClarVista Medical, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.